8-K current report · filed Jul 23, 2026

NovoCure Ltd (NVCR) 8-K Current Report: July 23, 2026

Item 2.02Item EX-99.1NVCR overview

Short answer

NovoCure Ltd (NVCR) filed an 8-K current report with the SEC on July 23, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results released for quarter ended June 30, 2026.

NovoCure Ltd 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results released for quarter ended June 30, 2026
  • Detailed results and management commentary available in Exhibit 99.1

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $183.6M, up 16% year over year, with global active patients up 18% to 5,128
  • Adjusted EBITDA $10.8M versus $(9.9)M, supporting management’s path toward profitability
  • Net loss narrowed to $15.7M, or $0.13 per share, from $40.1M, or $0.36, in Q2 2025
  • Optune Pax CE Mark expands European launch opportunity, with Germany first market and 285 U.S. patients
  • 2026 guidance raised: revenue $710M-$725M and Adjusted EBITDA $0M-$15M, versus prior ranges of $690M-$710M and $(15)M-$0ીએમ

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other NovoCure Ltd 8-K filings

Get the next NVCR 8-K as it lands

Follow NVCR for push alerts, or ask the research agent what this filing means.